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Autosomal dominant polycystic kidney disease with anticipation and
Caroli's disease associated with a PKD1 mutation. Autosomal dominant
polycystic kidney disease (ADPKD) is the most common renal hereditary
disorder. Clinical expression of ADPKD shows interfamilial and intrafa-
milial variability. We screened for mutations the 3' region of the PKD1
gene, from exon 43 to exon 46, in a family showing anticipation and
Caroli's disease and have found a 28 base pairs deletion in exon 46
(12801de128) and a new DNA variant in exon 43 (12184 C to G conserving
Ala 3991) segregating with the disease. The mutation should result in a
protein 44 amino acids longer than the wild-type PKD1. This PKDI
mutation manifests as typical adult-onset disease in the father, but in the
proband, a 26-year-old man, ADPKD was diagnosed as a newborn and
was associated with Caroli's disease at the age of 18 years. A renal biopsy
performed in childhood disclosed a predominance of glomerular cysts.
Mutation 12801de128 is the first molecular defect associated with Caroli's
disease and the PKD1 phenotype. The finding of the same mutation in two
different members of the same family with different expression of the
disease indicates that the phenotypic variation in ADPKD must be due to
modifying factors that may radically affect the course of the disease.
Autosomal dominant polycystic kidney disease (ADPKD) is the
most common renal inherited disorder affecting 1 in 1000 persons
[1] and accounting for 10% of patients on renal replacement
therapy (RRT) [21. It is characterized by the progressive renal cyst
development and enlargement as well as a wide array of extrare-
nal features [31. Several reports reveal a high intrafamilial and
interfamilial variability of the clinical expression of the disease [4,
51.
At least three different genes may cause ADPKD: PKD1, in
chromosome lopl3.3 [61 accounts for about 85% of the cases [7],
PKD2 at 4q13 to 23 [8—10] accounts for the remaining 15% and a
third locus still unmappcd causes the disease in some reported
families [1 1—13]. PKD2 has been proved to be a milder form of the
disease with a later age of onset of end-stage renal disease
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(ESRD) than PKD1 patients [14]. The PKD1 transcript consists
of 14,148 bp, distributed among 46 exons, spanning 52 kb. An
interesting feature of this gene is that all but 3.5 kb at the 3'end
of the transcript is encoded by a region repeated several times,
proximally in the same chromosome. Until now very few muta-
tions [15—19] have been reported in the PKDI gene, mainly due to
the this fact, and most of them are located in the non-repeated
3'region. Only one of these mutations has been reported in more
than one family [20].
The presence of anticipation, defined as beginning of ESRD at
least ten years earlier in the offspring than in the parent or the
presence of early-onset cases in a family, has been reported in
several ADPKD families [2, 14, 211. There is no molecular basis to
explain anticipation in ADPKD. The PKD1 gene has been fully
sequenced and there are no trinucleotide repeats larger than five
copies that could explain the phenomenon of anticipation as has
been found in some neurological disorders [22].
Hepatic involvement is extremely frequent in ADPKD. It
usually presents as polycystic liver disease (PLD), being more
frequent as the age increases, and it is more severe in women [23,
24]. PLD belongs to a family of liver diseases, characterized by an
overgrowth of biliary epithelium and supportive connective tissue,
called the hepatobiliary fibropolycystic diseases [25]. These disor-
ders include dilation of the extrahepatic and/or intrahepatic bile
ducts, segmental dilatation of intrahepatic bile ducts (Caroli's
disease), congenital hepatic fibrosis, autosomal recessive polycys-
tic kidney disease (ARPKD) and PLD. The common pathogenesis
for these entities may explain why the presence of these diseases
frequently overlaps. Hepatic fibrosis is always present in ARPKD
but it is rare in ADPKD [26]; moreover, Caroli's disease is quite
frequent in ARPKD [27, 28] but extremely infrequent in ADPKD
[29—32].
Here we describe a deletion of 28 bp in the PKDJ gene in two
members of the same family showing different expression of the
disease: a severely affected young adult with ADPKD and Caroli's
disease diagnosed as a newborn, and his father who has typical
adult onset ADPKD.
METHODS
Genomic DNA from 150 unrelated individuals was extracted
with the salting out method [33] and was amplified with several
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Fig. 1. Renal biopsy of the proband at two
months of age. Preserved renal tissue can be
found among tubular and glomerular cysts. An
arrow points a glomerular cyst.
primers that covered the DNA sequence from exon 43 to exon 46.
The results in the present work were obtained with primers JJ
(12666-12848 nt of PKD1 eDNA; exon 46) using a DMSO
containing buffer and annealing at 60°C with 1.5 mi MgC12 and
with primers DD (12084-12271 nt of PKDJ cDNA; exons 43 to 44)
with the same buffer and PCR conditions as JJ [171. The products
of 183 bp and 263 bp, respectively, were analyzed by SSCA (single
strand conformation analysis) with the silver staining technique
[341. The abnormal PCR fragments generated were sequenced
using ABI PRISM Dye Terminator Cycle Sequencing Ready
Reaction Kit in an ABI PRISM Genetic Analyzer 310 (Perkin
Elmer, Foster City, KS, USA). Microsatellites AC25-D16S291,
KG8-PKE1 and CW2-D16S663 were amplified and analyzed as
previously described [14J. The Gene Bank accession number of
the cDNA sequence used to number the nucleotides position is
L33243.
RESULTS
Clinical data
The proband is a 26-year-old man who was diagnosed as a
newborn of polycystic kidney disease due to palpation of enlarged
kidneys. A renal biopsy, performed at two months of age, dis-
closed a renal surface covered by multiple cysts of 5 mm of
diameter. Microscopical analysis showed multiple cysts of a
uniform size limited by cuboidal epithelium and separated by
scarce intercellular matrix in which renal tubuli and glomeruli
were embedded. There were also some cystic glomeruli (Fig. 1).
He did not follow any medical control until the age of 18 years
when in a routine analysis pancitopenia was discovered. Panci-
topenia was attributed to portal hypertension diagnosed in hemo-
dynamic studies. The cause of portal hypertension was supposed
to be either Caroli's disease associated with liver fibrosis or portal
cavernomatosis, which were both present in the patient. At the
age of 23 a slight deterioration of the renal function was discov-
ered and a renal sonography disclosed enlarged cystic kidneys.
At the time of the study, the creatinine was 4 mg/dl, the
creatinine clearance 20 ml/min, leukocytes 1400 per mm3, hemat-
ocrit 37%, platelets 39,000 per mm3 and prothrombin test 69%.
The sonography scan disclosed hepatomegaly with dilation of
intrahepatic bile ducts preferentially in the right lobe (Fig. 2),
portal cavernomatosis, splenomegaly and cystic kidneys of 17 cm
of diameter. Delayed views of a hepatobiliary scintigraphy 99mTc
DISIDA (diisopropyliminodiacetic acid) demonstrated retained
radiotracer, at 24-hours post-injection, preferentially in the right
lobe.
The father is 53 years old and has polycystic liver and renal
disease. He has been on RRT for the last three months. The
mother and the brother (24-years-old) showed no evidence of
ADPKD either clinically or at ultrasound. Two uncles were
diagnosed with ADPKD and started RRT at the age of 60 and 58,
respectively. The grandfather and the great-grandfather died at 58
and 50 years of age, respectively, due to uremia.
Molecular analysis
Linkage analysis using three microsatellites from the PKDJ region
(AC2.5-D16S291, KG8-PKD1 and CW2-D16S663) showed that the
parent had transmitted different alleles to his two sons (Fig. 3a).
The 3' end of the PKDJ genomic sequence of the father was
analyzed for mutations by SSCA and an abnormal fragment was
detected with the primers JJ [17]. As the SSCA pattern suggested
a deletion the PCR product was electrophoresed in a 4% agarose
gel where two fragments of 183 and 155 bp could be seen in the
affected individuals and only one fragment of 183 bp in normal
subjects. Only the father and the affected son have the mutation
(Fig. 3b). Direct sequencing showed a 28 bp deletion (12801del28)
in exon 46 (Fig. 3c). This mutation induces a frameshift after
amino acid 4200 and should result in a protein 44 amino acids
longer than the normal PKDJ protein. The mutation 12801de128
was not detected in a further screen of 150 normal chromosomes.
Another abnormal fragment in the SSCA was found with
primers DD. Direct sequencing showed a C to G transition (12184
C to G conserving Ala 3991) in exon 43. The same abnormal band
was present in the affected son (Fig. 3a). This change was not seen
in a further study of 300 chromosomes.
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Fig. 2. Sonography image of the right lobe of
the liver showing tubular (up) and sacular
(down) dilation of the intrahepatic bile ducts.
DISCUSSION
ADPKD is a multisystem disease with abnormalities in many
different organs. The extent of the affection of these organs may
vary greatly causing a great interindividual variability. The age of
onset of ESRD is the parameter that is most widely used to
differentiate the clinical expression of the disease [21]. In the
family presented in this study, not only the age of onset of ESRD
caused great intrafamilial variability but also the hepatic disease.
While the father has a typical PLD the son has a Caroli's disease
with hepatic fibrosis.
Two varieties of Caroli's disease have been described [35]. A
pure form characterized by ecstasies of the intrahepatic bile ducts
without further hystological abnormalities and a combined form
in which Caroli's disease is associated with periportal fibrosis
corresponding to congenital hepatic fibrosis. The association of
both types of Caroli's disease and autosomal recessive polycystic
kidney disease (ARPKD) has been well recognized in the litera-
ture [27, 28, 36], but the coexistence of ADPKD and Caroli's
disease is a rarely reported association [29—32]. The pathogenesis
of Caroli's disease seems to involve a partial arrest of the
embriogenesis of larger intrahepatic bile ducts (segmental ducts).
The presence of hepatic fibrosis implies that the defect is not only
present during the early stages of bile duct embriogenesis, but also
on a later stage of development of more peripheral biliary
ramifications (interlobular ducts) [361. The typical hepatic in-
volvement in ADPKD which is PLD and microbiliary hamartomas
(von Meyenburg complexes) invokes a factor arresting or perturb-
ing the remodeling of primitive biliary ducts in the later phases of
the development (intralobular ductules). Thus, in the case pre-
sented here there is an arrest of the biliary embriogenesis much
sooner than would be expected in a usual case of ADPKD.
Polycystine, the product of the PKDI gene, seems to be involved
in both renal and hepatobiliary embriogenesis. This is strongly
supported by the finding that polycystine is more highly expressed
in fetal than in adult kidney [371 and is also overexpressed in the
liver and the biliary fetal system [38], but it is highly speculative to
postulate than an abnormal polycystine may account for the
abnormal biliary organogenesis and an early onset renal disease.
There have been several reports of intrafamilial clinical heter-
ogeneity in ADPKD and anticipation [21, 5, 39], but there is only
one report disclosing the molecular defect in a case with antici-
pation. Peral et al described a Y3818X mutation in a severely
affected child. They found the same mutation in her clinically
normal twin brother and in her father who had typical adult-onset
disease [16]. Our analysis of one such family has revealed a
deletion of 28 bp in the 3' region of the PKD1 gene. This mutation
changes the open reading frame and should produce a protein
with additional 44 amino acids. Some other mutations have been
described in this region of PKDJ in families with adult onset
ADPKD [15, 17—19]. In contrast to many neurological diseases
where anticipation can be explained by the amplification of an
unstable DNA repeat in the coding or noncoding region of the
relevant genes [22], there are no trinucleotide repeats larger than
5 units in length in the PKDJ gene. Thus, the anticipation seen in
ADPKD is not due to a dynamic mutation within the PKD1 gene.
Different explanations may account for the intrafamilial vari-
ability seen in the family presented in this study. One possibility is
that there may be subtle changes in the PKD1 gene inherited from
the mother, which are not enough to cause the disease but may
influence the expression of the other allele and modify the
presentation of the disease. A two-hit model [40, 41] could also
account for the intrafamilial variability seen in this family with
different and more severe somatic mutations in the normal PKD1
allele in the son than in the father. It is also possible that the
proband has a de novo mutation in the other allele or in the same
PKD1 gene that is absent in the father. Eventually, modifying
genes may be one of the best explanations for the clinical
differences between ADPKD patients. Some modifying genes in
polycystic mouse models affecting the progression of the disease
have been described [42, 43], but nothing is yet known in humans.
The PKD2 gene may be one of these modifying genes as its
product has been proved to interact with polycystine through a
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coiled coil domain [44]. Thus, subtle changes in the PKD2 gene,
either de novo or inherited from the mother, could account for the
clinical differences seen in this family. Finally, since about 25% of
the general population have trinucleotide repeats of larger than
40 units (X. Estivill and M. Pujana, personal communication), it is
possible that genes with trinucleotide repeats present expansions
that influence the severity of ADPKD.
Infantile renal tissue of ADPKD patients surviving the neonatal
period is rarely available but the patient reported hereby under-
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went a renal biopsy at the age of two months. The most striking
feature of this renal biopsy was a predominance of glomerular
cysts. This finding has been reported in the literature in autopsies
of newborns and in fetuses with ADPKD [45—49] and has been
considered to be a common feature of early-onset ADPKD.
Although our patient will enter ESRD sooner than usual and this
may suggest that glomerular cysts imply a worse outcome, the
presence of glomerular cysts could also be a common finding in
ADPKD kidneys in the early stages of development. This last
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Fig. 3. A. Pedigree of the kindred. Symbols are: (0, U), unaffected; (•, affected; U, U, men; 0 females. Haplotypes from the PKD1 region are below
each symbol: microsatellite alleles: A, KG8; C, AC2.5; F, CW2. Mutation and the new described polymorphism are also indicated. B. PCR amplification
with primers JJ in which affected members show an heterozygous pattern, due to the deletion of 28 bp. C. Wild-type and mutant DNA sequence from
position 12649 in exon 46 and predicted protein sequence given in the one letter code (accession L33243). The predicted protein from mutant DNA
is 44 amino acids longer than the wild type. For the wild-type, the deleted DNA sequence is shown in bold; for the mutant, the amino acid sequence
changes caused by the mutation are shown in hold.
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hypothesis is supported by the fact that large cysts in adults can be
more difficult to identify hystologically as being glomerular and its
prevalence may be underestimated.
In summary, the family reported hereby discloses very different
phenotypes arising from the same mutation. Probably the coex-
istence of other genetic defects with this mutation may account for
the anticipation and/or the hepatic involvement seen in this
family. Mapping and characterization of modifying factors may
identify important indicators of the severity of the disease and its
hepatic involvement, and clarify the process of cystogenesis.
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